Year: 2021

Solar Alliance completes acquisition of first New York solar project

Written by Customer Service on November 16, 2021. Posted in Mergers And Acquisitions.

Project will begin generating recurring revenue in early 2022 TORONTO and KNOXVILLE, Tenn., Nov. 16, 2021 (GLOBE NEWSWIRE) — Solar Alliance Energy Inc. (‘Solar Alliance’ or the ‘Company’) (TSX-V: SOLR) is pleased to announce it has completed the acquisition of a 298 kilowatt (“kW”) project in New York State from Abundant Solar Power Inc. (“Abundant”). The project acquisition, first announced on May 26, 2021, represents the first project Solar Alliance will own and operate under a 30 year power purchase agreement. Construction will commence in early 2022. “The completion of this acquisition is a clear indication of the progress our team continues to make as we build out our project pipeline and begin building projects that we will own and operate,” said CEO Myke Clark. “This project is the first of several we plan to build, own...

Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update

Written by Customer Service on November 16, 2021. Posted in Earnings Releases And Operating Results.

Interim data update at SITC for ongoing ACTengine® IMA203 trial targeting PRAME demonstrated clinical responses across multiple solid tumor types during dose escalation phase Immatics to initiate three expansion cohorts for IMA203 targeting PRAME: monotherapy, combination with checkpoint inhibitor, and next–generation ACT approach Cash and cash equivalents as well as other financial assets of $200.6 million1(€173.2 million) as of September 30, 2021, funding company operations into 2023Tuebingen, Germany and Houston, TX, November 16, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported its financial results for the quarter ended September 30, 2021, and provided a business update on its progress...

AIM ImmunoTech Provides Third Quarter 2021 Business Update

Written by Customer Service on November 16, 2021. Posted in Earnings Releases And Operating Results.

OCALA, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the third quarter ended September 30, 2021 and provides a business update. Third Quarter 2021 Financial Highlights: As of September 30, 2021, AIM had cash, cash equivalents and marketable securities of $53.7 million, compared to $54.4 million as of December 31, 2020. Research and development expenses for the three months ended September 30, 2021 were $2.0 million, compared to $1.1 million for the three months ended September 30, 2020. General and administrative expenses for the three months ended September 30, 2021 were $1.8 million, compared to $2.1 million for the three months ended September 30, 2020. The net loss from operations for the three months ended September 30, 2021 was $3.8 million, or $0.08 per share,...

Entourage Health Reports Q3 Financial Results with $14.9 Million Record Revenue Representing 94% YOY Increase and Fourth Consecutive Quarter of Growth

Written by Customer Service on November 16, 2021. Posted in Earnings Releases And Operating Results.

Adult-Use net revenue for the quarter increased by 102% compared to last year Sales, general and administrative costs decreased by 16% compared to last year Strategic acquisition of craft cultivator CannTx will introduce new genetics, IP and cultivars Management to host conference call today at 10:00 a.m. Eastern TimeTORONTO, Nov. 16, 2021 (GLOBE NEWSWIRE) — Entourage Health Corp. (formerly WeedMD Inc.) (TSX-V:ENTG) (OTCQX:ETRGF) (FSE:4WE) (“Entourage” or the “Company”), a Canadian producer and distributor of award-winning cannabis products and brands, announced today its financial results for the three and nine months ended September 30, 2021. The Company recorded third quarter 2021 total revenue of $14.9 million, a 94% increase year-over-year, and net revenue of $10.8 million, up 71% from the prior year and reflecting higher...

MediWound Reports Third Quarter 2021 Financial Results

Written by Customer Service on November 16, 2021. Posted in Earnings Releases And Operating Results.

Third Quarter Revenues of $6.4 Million; Year-to-Date 2021 Revenues Increased 21% Clarity on Regulatory Pathway for Resubmission of NexoBrid BLA, Anticipated in Mid- 2022 EscharEx Phase 2 Program Top-Line Results Accelerated, Currently Expected in the First Quarter of 2022 Conference call begins today at 8:30 am ET YAVNE, Israel, Nov. 16, 2021 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced financial results for the third quarter ended September 30, 2021. Third Quarter and Recent Corporate and Financial Highlights:Total revenues for the third quarter of 2021 were $6.4 million, compared to $6.6 million in the third quarter of 2020Total revenues for the first nine...

Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts

Written by Customer Service on November 16, 2021. Posted in Public Companies.

– exoSTING resulted in localized STING pathway activation and dose-dependent immune activation – – Intratumoral administration of exoSTING was well tolerated and demonstrated tumor retention, no systemic exposure to STING agonist, and in a subset of patients, tumor shrinkage in injected and distal non-injected lesions – – Data on objective response rate and recommended Phase 2 dose selection for expansion anticipated 1H 2022 – – Codiak to host conference call and webcast today at 8:00 am ET – CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) — Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced positive initial data for exoSTING, a novel engineered exosome therapeutic candidate currently...

Stantec-Atkins-Dewberry team selected to support national flood mapping and risk mitigation for FEMA

Written by Customer Service on November 16, 2021. Posted in Public Companies.

The firm will provide engineering and technical support for the agency’s Risk MAP program as part of a joint venture EDMONTON, Alberta and NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) — TSX, NYSE:STN Leading global design firm Stantec, as part of the Strategic Alliance for Risk Reduction II (STARR II) Joint Venture, has been selected by FEMA to provide engineering and technical services for the National Flood Insurance Program under a five-year indefinite delivery/indefinite quantity contract valued at up to US$300 million. STARR II will support the agency’s Risk Mapping, Assessment, and Planning (Risk MAP) program throughout FEMA Regions 8, 9, and 10, which include 12 midwestern and western states, as well as Alaska, Hawaii, Guam, and the Northern Mariana Islands. Stantec, along with STARR II partners Atkins and Dewberry, have supported...

Ocean Power Technologies Acquires Marine Advanced Robotics

Written by Customer Service on November 16, 2021. Posted in Mergers And Acquisitions.

OPT Expands Offshore Intelligence Capabilities Through Addition of Autonomous USV Services MONROE TOWNSHIP, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (“OPT” or the “Company”) (NYSE American: OPTT), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced the Company closed on an acquisition of Marine Advanced Robotics, Inc. (“MAR”), a Richmond (San Francisco Bay Area), California-based developer and manufacturer of autonomous surface vehicles (ASVs). This acquisition immediately provides OPT with an established, innovative offshore product line that features roaming capability and highly complements the OPT business strategy. Marine Advanced Robotics, Inc. OverviewFounded in 2004, MAR is the developer of Wave Adaptive...

Form 8.3 – [Stock Spirits Group plc – 15 11 2021] – (HHL)

Written by Customer Service on November 16, 2021. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: HARGREAVE HALE LIMITED(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree STOCK SPIRITS GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing undertaken: For...

Marquee eGain Client Bags KM World Reality Award for 2021

Written by Customer Service on November 16, 2021. Posted in Public Companies.

SUNNYVALE, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) — eGain Corporation (NASDAQ: EGAN), a leading cloud platform provider for customer engagement automation, today announced that BT Consumer, one of its marquee clients, was selected for the KM Reality Award at the KMWorld Connect Conference 2021. Bestowed by KMWorld Magazine, the KM Reality Award recognizes an organization in which knowledge management is a positive reality, not just rhetoric. The award recipient should have demonstrated leadership in the implementation of knowledge management practices and processes, realizing measurable business benefits. To be considered for the award, the knowledge management program must have been in place for at least one year, received support from senior management, and defined metrics to evaluate the initiative and its impact on organizational...

Year: 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals